MTX poor-responder RA: what is the recommended next step?

MTX poor-responder RA: what is the recommended next step?

• A. Switch to HCQ
• B. Add bDMARDs
• C. Increase MTX
• D. Stop MTX

Answer: (B)

When methotrexate alone doesn’t achieve adequate control of rheumatoid arthritis, the recommended next step is to add a biologic DMARD to MTX. This combination targets inflammatory pathways more strongly than MTX alone, leading to higher rates of improvement, halting radiographic progression, and preserving function. Guidelines support stepping up to a bDMARD (and often continuing MTX to boost efficacy) when a patient has an inadequate response to MTX monotherapy. Increasing MTX dose or switching to hydroxychloroquine alone are less effective strategies in a poor responder, and stopping MTX removes a key disease-modifying cornerstone. If the disease remains active after adding a biologic, other options such as a different bDMARD or a targeted synthetic DMARD (like a JAK inhibitor) can be considered. Safety considerations include infection risk and the need for appropriate screening before starting a bDMARD.

When methotrexate alone doesn’t achieve adequate control of rheumatoid arthritis, the recommended next step is to add a biologic DMARD to MTX. This combination targets inflammatory pathways more strongly than MTX alone, leading to higher rates of improvement, halting radiographic progression, and preserving function. Guidelines support stepping up to a bDMARD (and often continuing MTX to boost efficacy) when a patient has an inadequate response to MTX monotherapy.

Increasing MTX dose or switching to hydroxychloroquine alone are less effective strategies in a poor responder, and stopping MTX removes a key disease-modifying cornerstone. If the disease remains active after adding a biologic, other options such as a different bDMARD or a targeted synthetic DMARD (like a JAK inhibitor) can be considered. Safety considerations include infection risk and the need for appropriate screening before starting a bDMARD.